Prognostic Influence of Loss of Blood Group A Antigen Expression in Pathologic Stage I Non-Small-Cell Lung Cancer;Influencia pronóstica de la pérdida de la expresión del antígeno del grupo sanguíneo A en el carcinoma no microcítico de pulmón en estadio I patológico

Archivos de Bronconeumologia

Volumn 48, Issue 2, 2012, Pages 49-54

  León Atance, Pablo ^a   Moreno Mata, Nicolás ^b   González Aragoneses, Federico ^c   Cañizares Carretero, Miguel ángel ^d   Poblet Martínez, Enrique ^a   Genovés Crespo, Marta ^a   García Jiménez, María Dolores ^a   Honguero Martínez, Antonio Francisco ^a   Rombolá, Carlos Alberto ^a   Simón Adiego, Carlos María ^c   Peñalver Pacual, Rafael ^c   Álvarez Fernández, Emilio ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Sección de Cirugía Torácica   (Spain)

Author keywords

Blood group antigen A (BAA); Lung adenocarcinoma; Non small cell lung cancer (NSCLC); Pathologic stage; Prognostic factors

Indexed keywords

BLOOD GROUP A ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; SURVIVAL RATE; AGED; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; FEMALE; IMMUNOHISTOCHEMISTRY; LARGE CELL LUNG CARCINOMA; MALE; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA;

EID: 85047699473     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.10.003     Document Type: Article

References (27)

1. Youlden D.R., Cramb S.M., Baade P.D. The International Epidemiology of Lung Cancer: Geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-831.
2. Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007, 8:784-796.
3. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
4. Goldstraw P. International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology 2009, Rx Press, Orange Park, FL.
5. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:694-705.
6. Chansky K., Sculier J.P., Crowley J.J., Giroux D., Van Meerbeeck J., Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009, 4:792-801.
7. Scott W.J., Howington J., Feigenberg S., Movsas B., Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S.
8. Tsuboi M., Ohira T., Saji H., Miyajima K., Kajiwara N., Uchida O., et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007, 13:73-77.
9. Szulman A.E. The histological distribution of blood group substances A and B in man. J Exp Med 1960, 111:785-800.
10. Yamamoto F., Clausen H., White T., Marken J., Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature 1990, 345:229-233.
11. Gao S., Worm J., Guldberg P., Eiberg H., Krogdahl A., Liu C.J., et al. Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer 2004, 109:230-237.
12. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001, 491:369-402.
13. Ravn V., Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000, 108:1-28.
14. Le Pendu J., Marionneau S., Cailleau-Thomas A., Rocher J., Le Moullac-Vaidye B., Clement M. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001, 109:9-31.
15. Masamune H., Kawasaki H., Abe S., Oyama K., Yamaguchi Y. Molischpositive mucopolysaccharides of gastric cancers as compared with the corresponding components of gastric mucosae. 1. Fractionation procedure of gastric cancer and gastric mucosa. Tohoku J Exp Med 1958, 68:81-91.
16. Lee J.S., Ro J.Y., Sahin A.A., Hong W.K., Brown B.W., Mountain C.F., et al. Expression of blood-group antigen A-a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991, 324:1084-1090.
17. Dresler C.M., Ritter J.H., Wick M.R., Roper C.L., Patterson G.A., Cooper J.D. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. Ann Thorac Surg 1995, 59:1069-1073.
18. Rice T.W., Tubbs R.R., Hoeltge G.A., Kirby T.J., Meeker D.P., Medendorp S.V., et al. Expression of blood group antigen A by stage I non-small cell lung carcinomas. Ann Thorac Surg 1995, 59:568-572.
19. León-Atance P., Moreno-Mata N., González-Aragoneses F., Cañizares-Carretero M.A., García-Jiménez M.D., Genovés-Crespo M., et al. Análisis multicéntrico de supervivencia y factores pronósticos en el carcinoma no microcítico de pulmón en estadio I patológico según la nueva clasificación TNM de 2009. Arch Bronconeumol 2011, 47:441-446.
20. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40:90-97.
21. Ulger A.F., Keklik T., Kumbasar O.O., Arbak P., Demirkazyk A., Gungor A., et al. Prognostic significance of blood group antigen expression of tumor tissue in lung cancer patients. Tumori 2002, 88:395-399.
22. Gwin J.L., Klein-Szanto A.J., Zhang S.Y., Agarwal P., Rogatko A., Keller S.M. Loss of blood group antigen A in non-small cell lung cancer. Ann Surg Oncol 1994, 1:423-427.
23. Graziano S.L., Tatum A.H., Gonchoroff N.J., Newman N.B., Kohman L.J. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clin Cancer Res 1997, 3:87-93.
24. Matsumoto H., Muramatsu H., Shimotakahara T., Yanagi M., Nishijima H., Mitani N., et al. Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas. Cancer 1993, 72:75-81.
25. Ichikawa D., Handa K., Withers D.A., Hakomori S. Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: Approach with A and B gene transfection. Cancer Res 1997, 57:3092-3096.
26. Ichikawa D., Handa K., Hakomori S. Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer 1998, 76:284-289.
27. Moldvay J., Scheid P., Wild P., Nabil K., Siat J., Borrelly J., et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000, 6:1125-1134.